枯草杆菌谷氨酰胺转胺酶的克隆及其在大肠杆菌中的融合表达

利用PCR技术 ,从枯草杆菌DB40 3染色体上扩增出谷氨酰胺转胺酶基因 ,将其克隆到大肠杆菌载体pET32a( + )中 ,成功构建谷氨酰胺转胺酶表达载体pET32-BTGase ,并转化大肠杆菌BL2 1 (DE3)。重组克隆在IPTG诱导下 ,表达出硫氧还蛋白 谷氨酰胺转胺酶 (Trx-BTGase)融合蛋白 ,表达量占细菌总蛋白量的 2 6%。利用金属螯合层析纯化菌体裂解上清中表达的融合蛋白 ,纯度超过 80 %,再通过分子筛层析进一步纯化得到融合蛋白纯品。酶活性分析表明表达的Trx-BTGase融合蛋白具有交联蛋白的活性 ,并发现Trx-BTGase融合蛋白和经凝血酶酶切后得到的BTGase单体都能催化牛血清白蛋白的聚合反应     

High-level expression, purification, and characterization of the recombinant grass carp pituitary adenylate cyclase-activating polypeptide

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP(38)) is a potent secretagog for growth hormone and gonadotropin in fish species. To obtain recombinant grass carp PACAP(38), its open reading frame was subcloned in pET32a(+) vector to express thioredoxin (Trx)-PACAP fusion protein in Escherichia coli BL21 (DE3). The resulting expression level of the thioredoxin-PACAP reached 36% of the total proteins, and more than 85% of fusion protein existed as soluble form. Using Ni(2+)-chelating affinity chromatography, 102 mg of Trx-PACAP(38) with a purity of 97% was obtained from 342 mg of crude proteins from a 1-liter culture of Escherichia coli. The purified Trx-PACAP specifically inhibited T98G human glioblastoma cell proliferation, but the fusion partner had no effect in this regard. Moreover, this inhibition was totally abolished by PACAP-specific antibody.     

MutL融合蛋白的高效表达及其伴侣功能研究(英文)

DNA错配修复蛋白MutL和其它的修复蛋白相互作用来共同完成大肠杆菌甲基介导的错配修复过程 .为研究修复蛋白MutL的体外生物功能构建了融合蛋白Trx His6 Linkerpeptide MutL(THLL)的表达载体并使其高效表达及易于纯化 .mutL基因片段是以E .coliK 12基因组为模板经PCR扩增获得 ,并通过基因的体外拼接成功构建了融合蛋白THLL表达载体pET32a linkerpeptide mutL .重组菌株E .coliAD4 94 (DE3) pET32a linkerpeptide mutL经过IPTG的诱导表达了融合蛋白THLL .收集菌体细胞、超声波破碎后离心取上清进行SDS PAGE分析 ,结果表明有一与预期分子量(84kD)相应的诱导表达条带出现 ,其表达量约占全细胞蛋白的 30 %且以可溶形式存在 .利用固定化金属离子 (Ni2 +)配体亲和层析柱纯化融合蛋白THLL ,其纯度达到 90 % .通过非变性凝胶电泳分析 ,对融合蛋白THLL在DNA错配修复过程中的分子伴侣生物功能进行了系统研究 .结果表明 ,THLL能增加融合蛋白Trx His6 Linkerpeptide MutS (THLS)与含有错配碱基DNA双链的结合 ,但受ATP的浓度变化影响很大     

Expression of human cardiac-specific homeobox protein in Escherichia coli

Human cardiac-specific homeobox protein cDNA (hCsx) was cloned into expression plasmid pET32a and fused with Escherichia coli thioredoxin (Trx). The Trx-Csx fusion protein was under the control of bacteriophage T7 promoter. When expressed in E. coli BL21(DE3), about half of the recombinant Trx-Csx products existed in the form of insoluble inclusion bodies. When coexpressed with human protein disulfide isomerase, more than 90% of Trx-Csx products accumulated in the soluble form in the cell lysate. The recombinant Csx fusion protein was purified by one-step metal-chelating affinity chromatography.     

人IGF-1在大肠杆菌中的可溶表达和纯化

目的:在大肠杆菌中的可溶表达和纯化人胰岛素样生长因子1(hIGF-1)。方法:根据hIGF-1的氨基酸序列和大肠杆菌密码子偏爱性,利用重叠延伸PCR的方法合成hIGF-1DNA序列,构建表达载体,在大肠杆菌OrigamiB(DE3)中与硫氧还蛋白TrxA融合表达,并通过盐析和镍柱亲合层析进行纯化。结果:SDS-PAGE分析显示,重组融合蛋白以可溶形式存在,分子量约为28kDa,占上清总蛋白的50%以上。经盐析和镍柱亲合层析进行纯化,目标蛋白纯度可达到90%左右。结论:复合干扰素在大肠杆菌中的高效可溶表达。     

抗菌肽CP10A在大肠杆菌中的融合表达

CP10A是一种由抗菌肽Indolicine经过序列改造,且对多数革兰氏阳性病源细菌具有较强抗菌活性的多肽序列。本研究根据已报道的CP10A氨基酸序列,兼顾大肠杆菌密码子偏好性,设计CP10A的核苷酸序列,利用PCR技术合成相应的DNA序列,后克隆构建重组表达载体pET32a（+）-CP10A,转入大肠杆菌AD494菌株。经IPTG诱导表达和15% SDS-PAGE电泳检测后发现产物以包涵体形式存在,且融合表达量占总蛋白的50%。在变性条件下经Ni-NTA亲合柱层析及复性,最终获得了较高纯度的可溶性重组蛋白。本研究首次实现了CP10A抗菌肽在大肠杆菌中的融合表达,为进一步研究其生物学活性及应用奠定了一定的基础,同时也为研究抗菌肽表达提供了一种方法。     

家蚕抗菌肽CD高效表达及其抗BmNPV感染作用

通过大肠杆菌JM109诱导家蚕,提取其脂肪体总mRNA后,通过RT-PCR得到cDNA,根据GenBank上家蚕抗菌肽CecropinD的cDNA序列,设计并合成引物,然后PCR扩增得到CecropinD肽基因并克隆到pGEM-T载体中,经过EcoRΙ和XhoI酶切,连接并将CecropinD肽基因插入pET32a表达载体中。用重组质粒pET32a-ecropinD转化大肠杆菌BL21(DE3),在IPTG诱导下,融合蛋白Trx-CecropinD以可溶形式得到高效表达,经SDS-PAGE检测显示分子量为23kDa与预期大小相符,表达量约为总蛋白的30%。融合蛋白经Ni2 柱纯化后通过肠激酶切割后释放为Trx(18kDa)和CecropinD(5kDa),最后通过超滤管分离得到重组抗菌肽。通过抑菌实验测得重组CecropinD对于革兰氏阴性及阳性菌均有抑菌活性。并将重组CecropinD与家蚕病毒BmNPV作用混合4h后,一起投喂家蚕,发现病毒感染力有明显降低,说明其有抗病毒感染作用。     

人干细胞因子模拟肽与c-JUN亮氨酸拉链融合蛋白的原核表达和生物学功能鉴定

将两种人干细胞因子(hSCF)模拟肽(CS2和LS2)分别与 c-jun亮氨酸拉链在大肠杆菌中融合表达,比较模拟肽与融合蛋白的生物学活性。通过搭桥PCR的方法,构建分别含有CS2和LS2与c-jun亮氨酸拉链融合蛋白及单独c-jun亮氨酸拉链编码序列的三种原核表达质粒pET30a-CSJ, pET30a-LSJ和pET30a-Jun,在E.coli BL21中进行表达,经镍柱和Sephadex G-50 柱 纯化后,SDS-PAGE和质谱法检测重组融合蛋白(CSJ,LSJ)和c-Jun的理化性质,MTT法检测融合蛋白刺激UT-7细胞增殖的活性。结果显示CSJ,LSJ和c-jun在E.coli中均呈20%左右表达,经纯化后其纯度达95%以上,分子量分别为7336.08,7991.54和6672.74。细胞学活性实验显示:与CS2和LS2相比,CSJ和LSJ促进UT-7细胞增殖的活性提高约1000倍。在大肠杆菌中成功表达了hSCF模拟肽与c-jun亮氨酸拉链融合蛋白, 融合蛋白活性显著高于合成的hSCF模拟肽。     

人脑源性神经营养因子基因的克隆及在大肠杆菌中表达

人脑源性神经营养因子基因的克隆及在大肠杆菌中表达何晓龙,路长林,王成海（第二军医大学神经生物学教研室,上海２００４３３）关键词神经营养因子;基因克隆脑源性神经营养因子（ｂｒａｉｎ－ｄｅｒｉｖｅｄｎｅｕｒｏｔｉｃ…ｉ。血。ｔｏｒ,ＢＤ贾助是Ｂａｄｅ等人...     

抗菌肽GK1在大肠杆菌中的融合表达

为高效表达抗菌肽GK1并避免GK1的高抗菌活性对大肠杆菌宿主菌的致命影响, 将经改造后的人胰岛素原(mhPI)与GK1的融合基因(mhPI-GK1)克隆到表达载体pET28a中, 构建出表达质粒pET28a-mhPI-GK1, 转化至大肠杆菌BL21(DE3)中进行表达。融合蛋白在大肠杆菌中以包涵体形式表达, 表达量占菌体总蛋白的20%。经CNBr裂解、阳离子交换层析和RP-HPLC纯化后, 每升发酵液可获得5.7 mg纯度大于97%的重组GK1。质谱检测显示重组GK1的分子量为2794.0 D, 抑菌活性实验表明纯化后的重组GK1和化学合成GK1具有相同的抗菌活性。为利用基因工程方法大规模生产GK1奠定了基础。     

一种新型融合蛋白(RGD)3/tTF的基因表达与活性分析

为了发展一种新型的融合蛋白(RGD)3/tTF用于肿瘤血管的选择性栓塞治疗,利用PCR技术重组(RGD)3/tTF融合基因,克隆于pET22b( )载体,表达于E.coliBL21(DE3)。用镍柱纯化融合蛋白。凝血实验与FⅩ活化实验检测融合蛋白tTF组分的活性。间接ELISA分析(RGD)3/tTF与αvβ3的特异结合能力。pET22b( )/(RGD)3/tTF重组质粒成功获得并表达于E.coliBL21(DE3)。纯化蛋白(RGD)3/tTF能有效诱发血液凝固,活化FⅩ。(RGD)3/tTF与αvβ3的特异结合能力比RGD/tTF提高了32%。新型融合蛋白(RGD)3/tTF已在E.coli系统成功表达,表达蛋白保持tTF的活性并显示比RGD/tTF更高的与αvβ3的结合能力。     

Codon preference optimization increases heterologous PEDF expression

Pigment epithelium-derived factor (PEDF) is widely known for its neurotrophic and antiangiogenic functions. Efficacy studies of PEDF in animal models are limited because of poor heterologous protein yields. Here, we redesigned the human PEDF gene to preferentially match codon frequencies of E coli without altering the amino acid sequence. Following de novo synthesis, codon optimized PEDF (coPEDF) and the wtPEDF genes were cloned into pET32a containing a 5' thioredoxin sequence (Trx) and the recombinant Trx-coPEDF or Trx-wtPEDF fusion constructs expressed in native and two tRNA augmented E coli hosts - BL21-CodonPlus(DE3)-RIL and BL21-CodonPlus(DE3)-RP, carrying extra copies of tRNAarg,ile,leu and tRNAarg,pro genes, respectively. Trx-PEDF fusion proteins were isolated using Ni-NTA metal affinity chromatography and PEDF purified after cleavage with factor Xα. Protein purity and identity were confirmed by western blot, MALDI-TOF, and UV/CD spectral analyses. Expression of the synthetic gene was ～3.4 fold greater (212.7 mg/g; 62.1 mg/g wet cells) and purified yields ～4 fold greater (41.1 mg/g; 11.3 mg/g wet cell) than wtPEDF in the native host. A small increase in expression of both genes was observed in hosts supplemented with rare tRNA genes compared to the native host but expression of coPEDF was ～3 fold greater than wtPEDF in both native and codon-bias-adjusted E coli strains. ΔGs at -3 to +50 of the Trx site of both fusion genes were -3.9 kcal/mol. Functionally, coPEDF was equally as effective as wtPEDF in reducing oxidative stress, promoting neurite outgrowth, and blocking endothelial tube formation. These findings suggest that while rare tRNA augmentation and mRNA folding energies can significantly contribute to increased protein expression, preferred codon usage, in this case, is advantageous to translational efficiency of biologically active PEDF in E coli. This strategy will undoubtedly fast forward studies to validate therapeutic utility of PEDF in vivo.     

Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli

We have previously reported that a variety of solid human tumor cell lines express a large number of receptors for interleukin-13 (IL-13). These receptors could be targeted with a chimeric fusion protein consisting of human IL-13 and a truncated form of Pseudomonas exotoxin (PE). We describe here optimization of critical steps involved in high yield expression of two recombinant chimeric fusion proteins for obtaining highly purified and biologically active cytotoxins in Escherichia coli. The chimeric constructs of human IL-13 and two 38 kDa truncated PEs: (i) PE38 and (ii) PE38QQR, (three lysine residues in PE38 at 590, 606, and 613 substituted with two glutamine and one arginine) were used for protein expression in pET prokaryotic expression vector system with kanamycin as a selection antibiotic. Our results suggest that fresh transformation of E. coli and induction by isopropyl-beta-D-thiogalactopyranoside (IPTG) for 6 h resulted in maximum protein expression. To further improve the yield, we used a genetically modified E. coli strain, BL21(DE3)pLysS, which carries a plasmid for lysozyme with a weak promoter that inhibits T7 RNA polymerase and minimizes protein production in the absence of IPTG. Use of this strain eliminated the need for lysozyme digestion of the induced bacteria to release inclusion bodies, which resulted in expression of purer protein as compared to the conventional BL21(DE3) strain. Additional protocol optimizations included 16 h solubilization of inclusion bodies, constitution of refolding buffer, and timing of dialysis. These proteins were finally purified by Q-Sepharose, mono-Q, and gel filtration chromatography. Between 14-22 and 21-28 mg highly purified and biologically active protein was obtained from 1L of BL21 (DE3) and BL21 (DE3) pLysS bacteria culture, respectively. As IL-13R targeting for brain tumor therapy offers an exciting treatment option, optimization of production of IL-13PE will enhance production of clinical grade material for Phase III clinical trials.     

水稻cDNA c73片段在大肠杆菌中的表达及其产物的纯化

曾以水稻蜡质基因５’调控区内一段３１ ｂｐ 片段为探针,用酵母单杂交法从水稻ｃＤＮＡ 文库中筛选出若干个其编码的蛋白可能与此３１ ｂｐ 片段结合的ｃＤＮＡ克隆,现将其中的ｐＣ７３ 克隆中的插入片段ｃ７３ 连接到含Ｈｉｓ６ 的表达载体ｐＥＴ２８ｃ（ ＋ ） 上,在大肠杆菌ＢＬ２１（ＤＥ３） 中进行诱导表达,并用ＮｉＮＴＡ 树脂纯化得到预期的融合表达产物。在合适的诱导表达条件下,融合表达产物主要以可溶形式存在于大肠杆菌细胞内;表达量占到大肠杆菌总蛋白的１０ ％ 左右;经ＮｉＮＴＡ 树脂亲和层析纯化得到的产物纯度达９５ ％ ,可供进一步研究之用。     

Expression and purification of soluble B lymphocyte stimulator from recombinant Escherichia coli

In this work, the expression conditions of fusion protein thioredoxin (Trx)-soluble B lymphocyte stimulator (sBLyS) in shake flask and bioreactor from the recombinant Escherichia coli BL21 (DE3) with a pET system encoding the fusion protein gene of Trx-sBLyS and the purification method of the sBLyS were optimized to effectively obtain the bioactive protein sBLyS with a high purity. A yield of about 250 mg Trx-sBLyS/g DWC (1686 mg Trx-sBLyS/L) and expression level of about 38.5% in soluble Trx-sBLyS were obtained in a 30 1 bioreactor after optimization of the fermentation conditions. After the completion of the optimized purification procedure in order of affinity chromatography, enzymatic cleavage with enterokinase and DEAE ion exchange chromatography, about 200 mg sBLyS per liter fermentation broth was obtained with a purity of about 95% and a yield of near 30%, respectively. Furthermore, the molecular weight (MW) and the isoelectric point (pI) of the purified sBLyS were determined by 2-D gel electrophoresis and SDS-PAGE analysis and estimated to be over 16 kDa and about pH 4.15, respectively. In addition, the bioactivities of the soluble Trx-sBLyS in fermentation broth and the purified sBLyS were tested by two kinds of analytical methods of bioactivity. The good fermentation yield and the satisfied, purified sBLyS product with high purity, yield and bioactivity demonstrated the sBLyS production procedure was promising in industry.     

Cloning, expression, and purification of the 27 kDa (MPT51, Rv3803c) protein of Mycobacterium tuberculosis

A limited number of proteins of Mycobacterium tuberculosis have been characterized so far for their use as potential candidates for diagnosis and vaccine studies. This study was aimed at cloning, expression, and purification of a 27 kDa protein (otherwise known as the MPT51 or Rv3803c protein) of M. tuberculosis. The Rv3803c gene was PCR amplified using primers that contain specific restriction sites. The amplified product was inserted initially into pTOPO and then sub-cloned into pET15b and pET24d vectors, such that the recombinant protein is predicted to contain an N-terminal or a C-terminal histidine tag, respectively. The recombinant plasmids were introduced into Escherichia coli BL21 (DE3) and the recombinant proteins were purified from the cytosolic fractions of the E. coli sonicates by nickel-NTA chromatography. The purity, molecular mass, and the conformation of the proteins were determined by high performance liquid chromatography (HPLC), matrix assisted laser desorption-ionization-time-of-flight (MALDI-TOF), and circular dichroism (CD) studies, respectively. The purified proteins were found to be immunogenic and useful for immunodiagnostic studies of tuberculosis by enzyme linked immunosorbent assay (ELISA), with a sensitivity of 71% and specificity of 95%.     

人组织性纤溶酶原激活物衍生物在大肠杆菌硫氧化还原蛋白融合表达系统中的表达

目的:克隆含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA序列(tPA355),将其在大肠杆菌融合蛋白表达系统中表达,并在体外复性使其具有激活纤溶酶原的生物活性。方法:采用RT-PCR技术从人黑色素瘤细胞Bowes中克隆出tPA355cDNA,然后在pET32a(+)BL21(DE3)大肠杆菌表达系统中表达,将表达出的融合蛋白Trx-tPA355(Thioredoxin,Trx)包涵体在体外进行变性、复性和纯化以使其具有激活纤溶酶原的生物活性。结果:测序结果表明本研究克隆的编码tPA中355个氨基酸密码子的cDNA序列与美国专利(公开号:5,587,159)中对应的序列完全一致,将其在pET32a(+)/BL21(DE3)大肠杆菌表达系统中表达可获得稳定表达的融合蛋白Trx-tPA355包涵体,该包涵体占菌体总蛋白的30%左右,此融合蛋白经变性、复性后具有激活纤溶酶原的生物活性。结论:含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA在大肠杆菌Trx融合蛋白表达系统中可获得稳定表达,表达的融合蛋白产物在体外经变性、复性后具有激活纤溶酶原的生物活性。     

Expression,refolding, and characterization of recombinant thrombopoietin/stem cell factor fusion protein in <Emphasis Type="Italic">Escherichia coli</Emphasis>

Thrombopoietin/stem cell factor (TPO/SCF) is a novel fusion protein that combines the complementary biological effects of TPO and SCF into a single molecule. In this study, TPO/SCF gene was cloned into pET32a and expressed as a thioredoxin (Trx) fusion protein with a C-terminal 6His-tag in Escherichia coli BL21(DE3) under the control of T7 promoter. Trx-TPO/SCF protein approximately accounted for 20% of the total bacterial proteins and was found to accumulate in inclusion bodies. Inclusion bodies were separated from cellular debris, washed with buffer containing 2 M urea, and solubilized with 8 M urea. The refolding of Trx-TPO/SCF was then carried out by an on-column method. Soluble Trx-TPO/SCF was characterized for its dose-dependent effects on promoting cells proliferation in both TF1 and Mo7e cell lines. rhTPO/SCF was released by thrombin digestion and further purified by Ni²⁺ affinity chromatography. Western blot analysis confirmed the identities of Trx-TPO/SCF and rhTPO/SCF.     

力生长因子在大肠杆菌中的表达及活性分析

MGF(Mechano-growth factor)是一种IGF-1变体形式, 研究发现该因子具有应力敏感性, 并且具有促进肌肉肥大、再生以及神经损伤修复的功能。通过RT-PCR从拉伸刺激的人成骨细胞中克隆MGF cDNA序列, 并去除5'端9 bp的序列, 使N端缺少对肠激酶(Enterokinase, EK)具有抑制作用的脯氨酸, 将截短型MGF (des(1-3) MGF) cDNA序列克隆入pET32a(+)质粒, 构建重组表达质粒。重组质粒转化E. coli BL21(DE3), 在30oC培养下以可溶形式表达融合蛋白Trx/ des(1-3)MGF, 采用离子交换层析和Ni2+金属亲和层析, 获得纯度95%以上的融合蛋白。再对融合蛋白EK酶切, rpHPLC分离获得纯度达98%的des(1-3)MGF, SDS-PAGE电泳及质谱分析蛋白分子量与理论值相符。生物活性实验显示, 所制备的des(1-3)MGF比des(1-3)IGF-1更显著的促进MC3T3-E1细胞的增值和迁移。     

鲎血细胞中脂多糖结合蛋白TALF在大肠杆菌中的表达研究

TALF(Tachyleus antilipoposaccharide factor)对细菌内毒素（LPS）的核心部分有抑制作用。研究TALF cDNA基因在大肠杆菌中的表达,首先将TALF cDNA基因分别插入大肠杆菌表达载体pGEX-4T-2、pET22b、pET28a中,构建重组表达质粒,转化于大肠杆菌BL21(DE3)。结果表明克隆于pET22b、pET28a中的TALF cDNA基因没有表达,而融合了GST的TALF基因（GST-TALF）能够在大肠杆菌中表达,并形成包涵体。从1L培养基中可获得4mg纯度为91%的GST-TALF融合蛋白。经复性和纯化后的融合蛋白GST-TALF几乎检测不到抑菌活性及LPS中和活性,但该融合蛋白经凝血酶消化后表现出明显的体外抑菌活性及LPS中和活性。